Table 6.8.

Other investigations performed with the supporting agents.

Name of the compound	Objectives	Outcome	References
Methylprednisolone	To describe the clinical characteristics and outcomes in patients who have developed ARDS from COVID-19 infection related pneumonia.	Methylprednisolone reduced the mortality incidence among COVID-19 infected patients. Death rate of patients treated with methylprednisolone-46%.	[127]
Methylprednisolone	To evaluate the potential and safety of corticosteroid for treatment of severe COVID-19 pneumonia.	Methylprednisolone administration resulted in improvement of SpO2. Betterment in absorption degree of the focus in chest CT. Less number of days required to normalize body temperature upon treatment with methylprednisolone.	[128]